Page 347 - ATP-P 11th Ed
P. 347

Rocephin  (Ceftriaxone Sodium)
               ®
        Salmeterol (Serevent )
                        ®
        Description: Long acting inhaled beta-2 adrenergic agonist; relaxes bronchial smooth mus-
        cle (bronchodilator)
        Indications:
        •  Relief of asthma
        •  Prevention/treatment of exercise-induced bronchospasm
        •  Treatment for chronic obstructive pulmonary disease (COPD)
        •  Nocturnal asthma
        •  HAPE prophylaxis/treatment
        Adult dose: 1 inhalation q12hr (twice daily)
        Pediatric dose: If more than 4 years of age, same as adult dose
        Contraindications: Hypersensitivity to salmeterol or other beta-2 agonists
        Pregnancy Category C
        Side-effects: Dry mouth/throat (sugarless hard candy or ice chips will often relieve  symptoms).
        Adverse reactions:                                                    SECTION 3
        •  Cardiovascular: tachyarrhythmias
        •  Neurologic: dizziness, headache, tremor
        •  Respiratory: throat irritation, also exacerbation of asthma (severe)
        Caution:
        •  This medication DOES NOT give immediate relief in the event of asthma attack or
          bronchospasm.
        •  This medication SHOULD NOT be used in combination with other long-acting inhaled
          beta-agonists (e.g., formoterol, salmeterol/fluticasone).
        •  Milk allergy; milk protein in the inhalation powder formulation
        TMEP use: Altitude Illness Protocol
        Septra  – See Trimethoprim-Sulfamethoxazole
             ®
        Serevent  – See Salmeterol
               ®
        Sildenafil (Viagra )
                     ®
        Class: PDE5 inhibitor.
        Action: Vasodilator with potential blood pressure-lowering effects
        Dose: 50mg
        Contraindications: Nitrates – Concomitant use of nitrates in any form. Tadalafil potentiates
        the hypotensive effects of nitrates.
        Pregnancy Category B


                                              ATP-P Handbook 11th Edition 337
   342   343   344   345   346   347   348   349   350   351   352